Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NovaBay Pharma ( (NBY) ) just unveiled an update.
On September 18, 2025, NovaBay Pharmaceuticals announced a one-time special cash dividend of $0.80 per share for its common stock, payable on September 29, 2025. Due to the dividend’s size, NYSE American advised that the company’s stock will trade with ‘due bills’ during the Dividend Right Period, affecting stockholders’ rights to the dividend. The company also plans to hold its 2025 Annual Meeting on October 16, 2025, to discuss strategic proposals, with CEO David Lazar expressing optimism about future strategic alternatives.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
NovaBay Pharma’s overall stock score reflects significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. While technical indicators show some bullish momentum, the valuation remains unattractive due to unprofitability. Positive corporate events, including a strategic shift and special dividend, provide some optimism for future prospects.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
NovaBay Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of products for the eye care market.
Average Trading Volume: 6,980,464
Technical Sentiment Signal: Sell
Current Market Cap: $10.19M
Find detailed analytics on NBY stock on TipRanks’ Stock Analysis page.